Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HER-2 x HBsAg
- Development stage
- Preclinical
- Lead developer
- Phoenix Biomolecular Engineering Foundation
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
**anti-HER-2 x HBsAg** refers to a bispecific monoclonal antibody designed to target both the human epidermal growth factor receptor 2 (HER2) and hepatitis B surface antigen (HBsAg). The HER2-binding arm is intended to target HER2-positive cancer cells, while the HBsAg-binding arm either targets hepatitis B virus-infected cells or uses HBsAg as a carrier/target for immune modulation. Bispecific antibodies such as this have applications in oncology, viral hepatitis, or as research tools. The specific mechanism is dual: inhibiting HER2-driven tumor growth and interacting with HBsAg. This agent is not listed among approved pharmaceuticals or clinical-stage drugs; it is likely a research or preclinical candidate. Mechanism: HER2 arm blocks HER2-mediated signaling and may cause antibody-dependent cellular cytotoxicity; HBsAg arm may support immune targeting of HBV-infected cells or serve as an antigen tether.
- Brand names
- anti-HER-2 x HBsAganti-HER2 x HBsAganti-HER 2 x HBsAg
- Other names
- anti-HER-2 x HBsAganti-HER2 x HBsAganti-HER 2 x HBsAg
02
Targets
HBsAg (Hepatitis B surface antigen)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on anti-HER-2 x HBsAg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HER-2 x HBsAg.